Fierce Pharma20h
British biotech rebrands as Octavian, seeking to establish new empire after setbacks in 2024
Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...
ADCT stock touches 52-week low at $1.42 amid market challenges
In a challenging market environment, Adc Therapeutics SA (ADCT) stock has reached a 52-week low, trading at $1.42, with a market capitalization of $138 million. According to InvestingPro analysis, the ...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Fierce Biotech18h
Pfizer's investigational candidate combo cuts prostate cancer progression by 49% in phase 1
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...
Agree Realty (ADC) Surpasses Q4 FFO and Revenue Estimates
Agree Realty (ADC) delivered FFO and revenue surprises of 0.97% and 0.75%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?